IMS Health chief nabs $25.9M in pay, topping J&J and Pfizer; Janssen's Stelara wins NICE nod for psoriatic arthritis;

@FiercePharma: ICYMI Friday: England to provide $GSK MenW vaccine to 3 million teens. FierceVaccines story | Follow @FiercePharma

@EricPFierce: GAO says FDA and DEA need to play better. The 2 can't even agree on what constitutes a drug shortage. FiercePharmaManufactuing article | Follow @EricPFierce

@CarlyHFierce: Endo Withdraws Proposal for Salix. Release | Follow @CarlyHFierce

> IMS Health Holdings ($IMS) gave its CEO a big pay boost for 2014, with a compensation package totaling $25.9 million, more than some of the biggest healthcare CEOs collect; the company went public last year, and CEO Ari Bousbib won a big stock award ahead of that offering. Report

> Johnson & Johnson's ($JNJ) anti-inflammatory drug Stelara won a thumbs up from U.K. cost-effectiveness watchdogs as a treatment for psoriatic arthritis. Report

> India's Lupin inked a deal to buy an additional 40% stake in the South African company Pharma Dynamics, gaining full control of the company in the process. Report

> The world's top 15 pharma companies saw their collective revenue drop to $546 billion from $555 billion last year, as the number of blockbuster meds dropped to 95 from 105. Report

Medical Device News

@FierceMedDev: Metabolon rides on last year's success with $5M in extended financing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: FDA expands indication of the only sublingual second-gen antipsychotic. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Metabolon rides on last year's success with $5M in extended financing. Story | Follow @EmilyWFierce

> St. Jude releases promising data on its heart failure system. Article

> Edwards and Medtronic turn up TAVR competition with positive study data. News

Biotech News

@FierceBiotech: Cidara Therapeutics makes a quick leap into the growing Q1 IPO queue. News | Follow @FierceBiotech

@JohnCFierce: We're up to about 600 responses to our bull vs. bubble survey. Today's your last shot at participating. Survey | Follow @JohnCFierce

@DamianFierce: Fun fact: The NEJM paper that got PCSK9 blockade rolling was published just nine years ago. Paper | Follow @DamianFierce

> Pulmatrix backs its way onto Wall Street with merger deal. Story

> Chiasma taps a new CEO as it rolls toward an FDA filing. Item

> R&D exec Tal Zaks leaps from flagging Sanofi to fast-growing Moderna. Report

Animal Health News

> Aratana Therapeutics reports lower Q4, full-year 2014 financials. News

> USDA to launch national equine study this spring. Item

> Hedge fund snaps up 5% of Valeant amid speculation of a Zoetis deal. More

> New FDA report finds banned antibiotics still showing up in dairy cow tests. Story

> USDA head calls halt to any new experiments at Nebraska facility. Article

Biotech IT News

> Y Combinator backs cancer drug combo testing service. Story

> Genomics England doles out $12M as sequencing yields early breakthroughs. More

> Google adds Tute database to burgeoning Genomics platform. Report

> UCB to host epilepsy digital tool hackathon. Item

> Apple turns 700M iPhone users into potential participants in massive virtual trials. Article

And Finally... An increase in fatty liver disease--and testing of new meds to treat it--have diagnostics makers looking for better methods of identifying the malady. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.